SIGN UP FOR UPDATES!
Sign up for Englemed updates from TwitterSign up for Englemed updates from Facebook
ENGLEMED
Contact Englemed
Our contact email address.
We can provide a specialist, tailored health and medical news service for your site.
Click here for more information
RSS graphic XML Graphic Add to Google
About Englemed news services - services and policies.
Englemed News Blog - Ten years and counting.
Diary of a reluctant allergy sufferer - How the British National Health Service deals with allergy.
BOOKS AND GIFTS THIS WAY!
BookshopFor books on women's health, healthy eating ideas, mental health issues, diabetes, etc click here
SEARCH THIS SITE
Google

WWW Englemed
Copyright Notice. All reports, text and layout copyright Englemed Ltd, 52 Perry Avenue, Birmingham UK B42 2NE. Co Registered in England No 7053778 Some photos copyright Englemed Ltd, others may be used with permission of copyright owners.
Disclaimer: Englemed is a news service and does not provide health advice. Advice should be taken from a medical professional or appropriate health professional about any course of treatment or therapy.
FreeDigitalPhotos
www.freedigitalphotos.net
FreeWebPhotos
www.freewebphoto.com
FROM OUR NEWS FEEDS
Lockdown leads to double unplanned pregnancies
Fri October 22nd - Unplanned pregnancies almost doubled during the first lockdown in the UK, a major study reports today. More
Promising development in treatment for glioblastoma multiforme
Fri October 22nd - A major advance in brain tumour research could pave the way for personalised treatment for the most deadly form of the disease, British scientists say. More
RECENT COMMENTS
On 09/10/2020 William Haworth wrote:
How long is recovery time after proceedure... on Ablation cuts atrial fibrillat...
On 08/02/2018 David Kelly wrote:
Would you like to write a piece about this to be i... on Researchers unveil new pain re...
On 23/10/2017 Cristina Pereira wrote:
https://epidemicj17.imascientist.org.uk/2017/06/21... on HIV breakthrough - MRC...
On 12/09/2017 Aparna srikantam wrote:
Brilliant finding! indeed a break through in under... on Leprosy research breakthrough...
On 01/07/2017 Annetta wrote:
I have been diagnosed with COPD for over 12 years.... on Seaweed plan for antimicrobial...
OUR CLIENTS
THIS WEEK'S STORIES
ENGLEMED HEALTH NEWS

First multi-variant COVID-19 vaccine trial starts

Tuesday September 21st 2021

The world’s first multi-variant COVID-19 booster vaccine is to undergo phase 1 trials among older adults in Manchester.

The GRT-R910 vaccine, launched by US pharmaceutical company Gritstone with The University of Manchester and Manchester University NHS Foundation Trust, is said to boost the immune response of first-generation COVID-19 vaccines to a wide array of variants of Sars-Cov-2.

The phase 1 trial is being offered to 20 volunteers over the age of 60 at the National Institute for Health Research Manchester Clinical Research Facility (NIHR MCRF) at Manchester Royal Infirmary, part of Manchester University NHS Foundation Trust (MFT).

The study will examine dose, safety, tolerability, and immunogenicity of GRT-R910 at two dose levels at least four months after the second administration of their initial vaccine.

Data evaluating the vaccine is expected in the first quarter of 2022 and results from the preclinical studies leading up to the development of the vaccine will be jointly published by Gritstone and the National Institutes of Health later in the year.

GRT-R910, created as part of Gritstone’s CORAL programme, is a self-amplifying mRNA second generation SARS-CoV-2 vaccine (SAM), which delivers antigens from both the spike and non-spike proteins.

SAM vaccines work by inducing CD8+ T cells and antibodies that can neutralise the virus and prevent it binding to and infecting cells.

The researchers hope it provide robust and persistent immunity and could lead to lowering vaccine doses or eliminate the need of repeat administrations.

Dr Andrew Allen, co-founder, president and chief executive officer of Gritstone, said: “Our SAM COVID-19 vaccine is designed to drive robust CD8+ T cell responses, in addition to strong neutralising antibody responses, offering the promise of longer lasting immunity.

“Since viral surface proteins like the spike protein are evolving and sometimes partially evading vaccine-induced immunity, we designed GRT-R910 to have broad therapeutic potential against a wide array of SARS-CoV-2 variants by also delivering highly conserved viral proteins that may be less prone to genetic variation in the virus.

“Our hypothesis is that a different vaccine such as GRT-R910 might complement the primary immune response from pre-existing vaccination with a first generation COVID vaccine in such a way that it would provide more benefit than an additional dose of the same vaccine.”

Professor Andrew Ustianowski, clinical lead for the NIHR COVID Vaccine Research Programme, said: “We now know the immune response to first generation vaccines can wane, particularly in older people. Coupled with the prevalence of emerging variants, there is a clear need for continued vigilance to keep COVID-19 at bay.

“We think GRT-R910 as a booster vaccination will elicit strong, durable, and broad immune responses, which are likely to be critical in maintaining protection of this vulnerable elderly population who are particularly at risk of hospitalisation and death.”

Professor Ian Bruce, from The University of Manchester, chair of the Manchester COVID-19 Research Rapid Response Group (RRRG), added: “We’re tremendously excited that this promising vaccine is to be trialled here in Manchester. As the only European site for this study, it is testament to the way our academic and clinical researchers have come together as part of the ‘One Manchester R&I’ approach to answer the questions the world needs answers to.

“Though the vaccine is being trialled in the over 60s, future studies will also examine its efficacy in other-vulnerable populations.

“If successful, we feel it has the potential to play a significant role in the battle against COVID-19, which has so devastated vulnerable populations across the globe.”

GRT-R910 is also being investigated as part of a US National Institute of Health sponsored Phase 1 study.

Additional trials of the CORAL platform, including an additional Phase-1 trial are planned, which will inform the future development of CORAL, Gritstone’s SARS-COV-2 second generation vaccine programme.

Tags: Flu & Viruses | Pharmaceuticals | UK News

Printer friendly page Printer friendly page

Comment on this article:

Name:
Email:
Comment:
<a>,<b> & <p> tags allowed
Please enter the letters displayed:
(not case sensitive)
CATEGORIES